TB-500 + AOD-9604 Stack: Complete Protocol, Dosing, and What the Evidence Actually Shows

What These Two Peptides Actually Are

TB-500 and AOD-9604 address different physiological targets, which is why practitioners combine them. Understanding each peptide individually makes the stack logic much easier to evaluate.

TB-500: Thymosin Beta-4 Synthetic Fragment

TB-500 is a synthetic, water-soluble fragment of thymosin beta-4 (TB4), specifically the actin-binding tetradecapeptide sequence Ac-SDKPDMAEIEKFDKS. Thymosin beta-4 is a 43-amino-acid ubiquitous intracellular peptide found at concentrations up to 500 mcM in platelets and wound fluid. Its primary function involves G-actin sequestration, which modulates cytoskeletal reorganization and cell migration during tissue repair [1].

Animal models consistently show TB4 accelerates dermal, corneal, and cardiac wound healing. A 2010 study published in the Annals of the New York Academy of Sciences demonstrated that thymosin beta-4 promoted cardiomyocyte survival and angiogenesis after myocardial infarction in rodent models, effects attributed to Akt/PKB pathway activation [2]. The commercially distributed TB-500 peptide is the presumed active fragment responsible for these downstream effects, though direct comparative bioequivalence data between TB-500 and full-chain TB4 in humans does not yet exist in peer-reviewed literature.

AOD-9604: The Lipolytic Fragment

AOD-9604 isolates residues 176-191 of the human growth hormone C-terminus. The original rationale was to retain GH's fat-burning properties while eliminating the IGF-1-driven anabolic and proliferative effects that carry long-term safety concerns [3]. In preclinical work, AOD-9604 stimulated lipolysis in adipocytes and reduced fat mass in obese rodent models without measurable effects on IGF-1, insulin, or blood glucose [4].

Metabolic Technologies Inc. Ran Phase I and Phase II clinical trials evaluating AOD-9604 as an obesity treatment. The compound achieved a favorable short-term safety profile, but Phase IIb trials did not demonstrate statistically significant weight loss over placebo at doses up to 1 mg/day in human subjects [5]. The FDA has not approved AOD-9604 for any indication.

Why Practitioners Stack These Two Peptides

The pairing appeals to practitioners working in sports medicine, anti-aging, and body recomposition because the two peptides act through separate, non-competing mechanisms.

Non-Overlapping Receptor Pathways

TB-500 does not bind GH receptors or affect IGF-1 signaling. AOD-9604 does not interact with actin-binding proteins or influence the cytoskeletal pathways that drive TB-500's repair effects [1, 4]. This means the two compounds are not competing for the same downstream target, which reduces the theoretical risk of additive toxicity compared to stacking two peptides that share receptor families.

Practical Goals the Stack Targets

The most common clinical scenario involves an individual recovering from a soft-tissue injury who also wants to reduce body fat percentage during the recovery period when normal training is restricted. TB-500 addresses the tissue-repair side; AOD-9604 targets fat mobilization during caloric restriction without requiring high-impact exercise to produce a lipolytic stimulus.

A second common scenario is the performance athlete in an off-season phase seeking simultaneous connective-tissue conditioning and a gradual reduction in body fat before returning to competition.

Both scenarios rely on complementary goals rather than synergistic receptor interaction, so the "stack" label here means concurrent use of two independent agents rather than a pharmacodynamic combination in the strict sense.

Mechanisms in Detail

How TB-500 Promotes Tissue Repair

The actin-sequestering activity of thymosin beta-4 reduces the pool of monomeric G-actin available for polymerization, which paradoxically promotes lamellipodia formation and directional cell migration in fibroblasts, endothelial cells, and keratinocytes [1]. This migration is necessary for wound closure and angiogenesis. Published rodent data show that TB4 administration after cardiac ischemia reduced infarct size and improved fractional shortening, with Akt phosphorylation as the proposed intracellular mediator [2].

Tendon and ligament repair is less well characterized at the molecular level, but in vivo equine studies (horses are a well-accepted large-animal model for tendinopathy) showed improved collagen fiber alignment and reduced healing time in superficial digital flexor tendons treated with TB4-containing preparations [6]. The relevance of these findings to subcutaneous TB-500 administration in humans requires careful interpretation, since route, dose, and species differences are substantial.

How AOD-9604 Drives Fat Loss

AOD-9604 activates the beta-3 adrenergic receptor on adipocytes, stimulating intracellular cAMP production and subsequent hormone-sensitive lipase (HSL) activation [4]. This is the same downstream pathway activated by epinephrine during aerobic exercise, which is why the peptide is often described as producing an "exercise-like" lipolytic signal. Unlike full-length GH, AOD-9604 does not appear to stimulate hepatic IGF-1 secretion at doses tested in clinical trials, an observation confirmed across the Phase I and Phase IIa data packages submitted to the FDA [5].

One in vitro study in 3T3-L1 adipocytes found that AOD-9604 inhibited lipogenesis and stimulated lipolysis at concentrations of 10-100 nM, with effects comparable to those of full-length recombinant human GH in the same assay system [4]. The clinical translation of in vitro lipolytic assays is notoriously unreliable, and the failed Phase IIb trial is the more relevant data point for realistic expectations.

Complete Dosing Protocol

No peer-reviewed RCT has tested this stack in humans. The dosing framework below synthesizes animal pharmacokinetic data, the Phase I/II clinical trial doses used for AOD-9604, and practitioner-reported protocols circulating in sports medicine literature. Evidence quality is low for the specific combination.

TB-500 Dosing

Loading phase (weeks 1-4): 5 mg subcutaneous injection, twice weekly. Injections are typically spaced 3-4 days apart to maintain relatively steady tissue concentrations. Preferred injection sites are the abdomen or thigh given the low injection volume (usually reconstituted in 1-2 mL bacteriostatic water).

Maintenance phase (weeks 5-12): 2-2.5 mg subcutaneous injection, twice weekly. Some practitioners drop to once weekly at this stage if the primary injury has resolved, using the maintenance phase purely for connective-tissue conditioning.

Cycle duration: 8-12 weeks is the most commonly reported window. No safety data exists for continuous use beyond 16 weeks in humans.

Reconstitution: TB-500 is typically supplied lyophilized. Reconstitute with bacteriostatic water (not sterile water, to allow multi-dose use). Use within 28 days of reconstitution when refrigerated at 2-8°C.

AOD-9604 Dosing

Standard dose: 300 mcg subcutaneous, once daily. Some protocols report 500 mcg daily for individuals with BMI above 30, though no dose-response RCT supports the higher dose.

Timing: Administer in a fasted state, either first thing in the morning or at least 30 minutes before the first meal. Food intake (particularly carbohydrates) blunts GH receptor signaling pathways, which may reduce AOD-9604's lipolytic activity even though the peptide does not directly bind the classical GH receptor.

Cycle duration: 12-16 weeks is common. The Phase IIb trials ran 24 weeks with no serious adverse events reported, so longer cycles are not necessarily unsafe, but efficacy data beyond 12 weeks is absent.

Stack Timing Within a Single Day

TB-500 is not time-sensitive relative to meals. Administer AOD-9604 first (fasted). Wait 30-60 minutes. Then eat and, on TB-500 dosing days, administer TB-500 any time thereafter. There is no documented pharmacokinetic interaction that requires separating the injections by more than a few minutes, but the AOD-9604 fasting requirement is the governing constraint.

Evidence Gaps and Honest Limitations

The evidence base for this stack has real gaps that any clinician or informed patient must weigh.

No Human RCT for the Combination

Neither peptide has been studied together in a controlled human trial. The mechanistic rationale for combining them is sound, but mechanism-based reasoning has failed to predict clinical outcomes repeatedly across pharmacology. AOD-9604 is itself the clearest example: strong animal data and mechanistic logic did not translate to meaningful weight loss in Phase IIb human trials [5].

TB-500 Human Data Is Almost Absent

TB4 (not the truncated TB-500 fragment) has been studied in a small Phase I cardiac trial (RegeneRx Biopharmaceuticals, ClinicalTrials.gov NCT00027612) for dry eye and cardiac indications, showing acceptable safety but no large efficacy signals in humans [7]. The commercially sold TB-500 fragment has not been the subject of a published Phase I human pharmacokinetic study. Practitioners and patients are extrapolating from animal data and the full-chain TB4 human safety data, which is a significant extrapolation.

Regulatory Status

Neither TB-500 nor AOD-9604 holds FDA approval for any human indication. AOD-9604 was granted Generally Recognized as Safe (GRAS) status for use as a food ingredient by the FDA in 2014 at very low doses, but this does not apply to the injectable doses used in peptide protocols [5]. The FDA issued a memorandum in 2023 restricting compounding pharmacies from producing several peptides, and practitioners should verify current compounding regulations in their jurisdiction before prescribing or acquiring these compounds [8].

Contamination and Purity Risks

Research-grade peptides purchased outside licensed compounding pharmacies carry documented contamination risks. A 2018 JAMA Internal Medicine analysis of online peptide and SARMs suppliers found that only 52% of products contained the labeled compound at the labeled concentration, with bacterial contamination in 25% of samples [9]. This is not a theoretical risk.

Side Effects and Safety Considerations

TB-500 Side Effect Profile

Reported side effects in animal studies and anecdotal human reports include transient fatigue in the first 1-2 days after injection, mild head rushness or lightheadedness, and localized injection-site irritation. The most frequently cited theoretical concern is that thymosin beta-4 promotes angiogenesis, which raises a question about whether it could support vascularization of occult tumors. No published clinical evidence confirms this risk in humans, but it means TB-500 is generally avoided in individuals with a personal history of cancer.

AOD-9604 Side Effect Profile

Phase I and Phase IIa data showed a profile comparable to placebo. Common reports included mild injection-site redness and transient nausea [5]. Because AOD-9604 does not measurably raise IGF-1, the theoretical risks of acromegaly-like side effects seen with full GH or some GH secretagogues do not apply here. Hypoglycemia was not reported in clinical trials, consistent with the compound's lack of insulin-modulating activity.

Absolute Contraindications for the Stack

Neither peptide should be used in:

• Pregnancy or breastfeeding (no safety data)
• Active or recent malignancy (theoretical angiogenesis concern for TB-500)
• Age <18 years (no pediatric data)
• Individuals with hypersensitivity to any component of either peptide

What Realistic Outcomes Look Like

Practitioners using this stack in body recomposition contexts report subjective improvements in joint and tendon comfort within 3-4 weeks of TB-500 loading, consistent with the angiogenic and anti-inflammatory mechanisms documented in animal models [2, 6]. Fat loss attributable specifically to AOD-9604 is harder to isolate because most individuals using this stack also modify diet and exercise simultaneously.

The Phase IIb AOD-9604 trials, which were the most rigorous test of the compound in isolation, did not demonstrate statistically significant weight loss versus placebo [5]. "The antiobesity effects seen in preclinical studies were not replicated in the Phase IIb human trial at doses up to 1 mg/day," as summarized in the Metabolic Technologies trial summary submitted to the FDA. This finding does not make AOD-9604 useless, but it does mean expecting meaningful scale weight reduction from the peptide alone is not evidence-supported.

TB-500's contribution to accelerated recovery from soft-tissue injuries is better supported in animal models, though the absence of human RCT data means any practitioner using it is operating outside the standard of care.

Monitoring While on This Stack

Baseline Labs Before Starting

Before beginning this stack, obtain:

• Complete metabolic panel (CMP)
• Fasting insulin and fasting glucose
• IGF-1 (to confirm AOD-9604 is not producing unexpected IGF-1 elevation)
• CBC with differential
• Thyroid panel (TSH, free T4)

On-Cycle Monitoring

Recheck IGF-1 at week 6. If IGF-1 has risen more than 30 ng/mL above baseline, stop AOD-9604 and reassess the peptide source (purity issues may have introduced full-length GH or a GH secretagogue contaminant). Recheck CMP at week 12. No specific TB-500 serum marker currently exists for monitoring purposes.

Off-Cycle Considerations

Standard practice in peptide medicine calls for an off-cycle period at least equal to the on-cycle duration before repeating. For a 12-week cycle, that means a 12-week break. This is convention rather than evidence-based pharmacokinetics, since half-lives for both compounds are measured in hours to days rather than weeks.

Sourcing and Legal Considerations

In the United States, these peptides are not scheduled controlled substances, but they are not approved drugs, and the legal framework governing their sale and use is complex. Licensed compounding pharmacies operating under 503A or 503B status can legally produce peptides for patient-specific prescriptions, but the FDA's updated compounding guidance must be checked against the specific peptide in question [8]. Purchasing from offshore or "research chemical" vendors carries purity risks and potential customs issues.

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency states that "unapproved GH-related peptides and secretagogues should not be prescribed outside of IRB-approved research protocols," a standard that many practitioners in anti-aging medicine operate outside of [10]. Clinicians should document informed consent explicitly, covering the investigational nature of these compounds.